Kevin P. Campbell

Nomenclature of voltage-gated sodium channels

Voltage-gated Ca2+ channels mediate calcium influx in response to membrane depolarization and regulate intracellular processes such as contraction, secretion, neurotransmission, and gene expression. They are members of a gene superfamily of transmembrane ion channel proteins that includes voltage-gated K+ and Na+ channels. The Ca2+ channels that have been characterized biochemically are complex proteins composed of four or five distinct subunits, which are encoded by multiple genes. The α1 subunit of 190–250 kDa is the largest subunit, and it incorporates the conduction pore, the voltage sensor and gating apparatus, and the known sites of channel regulation by second messengers, drugs, and toxins. An intracellular β subunit and a transmembrane, disulfide-linked α2δ subunit complex are components of most types of Ca2+ channels. A γ subunit has also been found in skeletal muscle Ca2+ channels, and related subunits are expressed in heart and brain. Although these auxiliary subunits modulate the properties of the channel complex, the pharmacological and electrophysiological diversity of Ca2+ channels arises primarily from the existence of multiple forms of α1 subunits. Mammalian α1 subunits are encoded by at least ten distinct genes. Historically, various names have been given to the corresponding gene products, giving rise to distinct and sometimes confusing nomenclatures. In 1994, some of us proposed a unified nomenclature based on the most widely accepted system at the time: α1 subunits were referred to as α1S for the original skeletal muscle isoform and α1A through α1E for those discovered subsequently (Birnbaumer et al. 1994xBirnbaumer, L., Campbell, K.P., Catterall, W.A., Harpold, M.M., Hofmann, F., Horne, W.A., Mori, Y., Schwartz, A., Snutch, T.P., Tanabe, T. et al. Neuron. 1994; 13: 505–506Abstract | Full Text PDF | PubMed | Scopus (264)See all ReferencesBirnbaumer et al. 1994). Since then, four new α1 subunits have been identified, which were named α1F through α1I.Ca2+ currents recorded in different cell types have diverse physiological and pharmacological properties, and an alphabetical nomenclature has also evolved for the distinct classes of Ca2+ currents. L-type Ca2+ currents require a strong depolarization for activation, are long lasting, and are blocked by the organic L-type Ca2+ channel antagonists, including dihydropyridines, phenylalkylamines, and benzothiazepines. They are the main Ca2+ currents recorded in muscle and endocrine cells, where they initiate contraction and secretion. N-type, P/Q-type, and R-type Ca2+ currents also require strong depolarization for activation. They are unaffected by L-type Ca2+ antagonist drugs but are blocked by specific polypeptide toxins from snail and spider venoms. They are expressed primarily in neurons, where they initiate neurotransmission at most fast synapses. T-type Ca2+ currents are activated by weak depolarizations and are transient. They are resistant to both organic antagonists and to the snake and spider toxins used to define the N- and P/Q-type Ca2+ currents. They are expressed in a wide variety of cell types, where they are involved in shaping the action potential and controlling patterns of repetitive firing.As new Ca2+ channel genes are cloned, it is apparent that these two alphabetical nomenclatures will overlap at α1L, which may not mediate an L-type Ca2+ current and therefore may create confusion. Moreover, the present alphabetical nomenclature does not reveal the structural relationships among the α1 subunits, which can be grouped into three families: (1) α1S, α1C, α1D, and α1F; (2) α1A, α1B, and α1E; and (3) α1G, α1H, and α1I. The complete amino acid sequences of these α1 subunits are more than 70% identical within a family but less than 40% identical among families. These family relationships are illustrated for the more conserved transmembrane and pore domains in Figure 1Figure 1. Division of calcium channels into these three families is phylogenetically ancient, as representatives of each are found in the C. elegans genome. Ideally, a nomenclature for Ca2+ channel α1 subunits should provide a systematic organization based on their structural relationships and should be coordinated with nomenclatures for the other families of voltage-gated ion channels of different ionic selectivities (ie., K+ and Na+).Figure 1Phylogeny of Voltage-Gated Ca2+ Channel α1 SubunitsOnly the membrane-spanning segments and the pore loops (∼350 amino acids) are compared. First, all sequence pairs were compared, which clearly defines three families with intrafamily sequence identities above 80% (CaV1.m, CaV2.m, CaV3.m). Then, a consensus sequence was defined for each family, and these three sequences were compared to one another, with interfamily sequence identities of ∼52% (CaV1.m versus CaV2.m) and 28% (CaV3.m versus CaV1.m or CaV2.m).View Large Image | View Hi-Res Image | Download PowerPoint SlideFor these reasons, we wish to propose a new nomenclature of voltage-gated Ca2+ channels (Table 1Table 1), which is more systematic and mimics the well-defined K+ channel nomenclature (Chandy et al., 1991xChandy, K.G. Nature. 1991; 352: 26Crossref | PubMedSee all ReferencesChandy et al., 1991). This nomenclature uses a numerical system (KV1.1, KV2.1, KV3.1, etc.) to define families and subfamilies of K+ channels based on similarities in amino acid sequences. In a similar manner, we propose that Ca2+ channels should be renamed using the chemical symbol of the principal permeating ion (Ca) with the principal physiological regulator (voltage) indicated as a subscript (CaV). The numerical identifier would correspond to the CaV channel α1 subunit gene family (1 through 3 at present) and the order of discovery of the α1 subunit within that family (1 through m). According to this nomenclature, the CaV1 family (CaV1.1 through CaV1.4) includes channels containing α1S, α1C, α1D, and α1F, which mediate L-type Ca2+ currents (Table 1Table 1). The CaV2 family (CaV2.1 through CaV2.3) includes channels containing α1A, α1B, and α1E, which mediate P/Q-type, N-type, and R-type Ca2+ currents, respectively (Table 1Table 1). The CaV3 family (CaV3.1 through CaV3.3) includes channels containing α1G, α1H, and α1I, which mediate T-type Ca2+ currents (Table 1Table 1). When specific reference to the α1 subunit within the Ca2+ channel complex is intended, the designation α11.m, α12.m, or α13.m may be used, where the numeral m represents the individual gene/protein within the family. Where applicable, lowercase letters are used to distinguish alternatively spliced variants (e.g., CaV1.2a corresponds to channels containing the cardiac variant of the former α1C). Such a systematic nomenclature has proved successful for the KV channel proteins. Its strength resides in the rational basis derived from the structural relationships among the channel proteins and the ease and precision with which new channels can be added.Table 1Proposed Nomenclature for Cloned Voltage-Gated Ca2+ Channel α1 SubunitsNameFormer NamesAccession NumberGene Name and Human ChromosomeSplice TypesFormer NamesPrimary TissuesCav1.1 α11.1α1S, α1Skm, CaCh1X05921CACNA1S; 1q31-32skeletal muscleCav1.2α1C, rbC, CaCh2CaCh2, X15539CACNA1C; 12p13.3Cav1.2aα1C-aheartα11.2Cav1.2bα1C-bsmooth musclerbC-I, M67516; rbC-II, M67515Cav1.2cα1C-bbrain, heart, pituitary, adrenalCav1.3 α11.3α1D, rbD, CaCh3M76558CACNA1D; 3p14.3brain, pancreas, kidney, ovary, cochleaCav1.4α1FAJ224874CACNA1F; Xp11.23retinaα11.4Cav2.1α1A, rbA, CaCh4, BIrbA, M64373; BI-1, X57476CACNA1A; 19p13Cav2.1aBI1brain, cochlea, pituitaryα12.1BI-2, X57477Cav2.1bBI2brain, cochlea, pituitaryCav2.2α1B, rbB, CaCh5, BIIIrbB, M92905; BIII, D14157;CACNA1B; 9q34Cav2.2aα1B-1brain, nervous systemα12.2human α1B, M94172Cav2.2bα1B-2brain, nervous systemCav2.3α1E, rbE, CaCh6, BIIrbE, L15453, BII-1, X67855;CACNA1E; 1q25-31Cav2.3aBIIbrain, cochlea, retina, heart,α12.3human α1E, L29384pituitaryCav2.3bBII2brain, cochlea, retinaCav3.1α1GAF027984; AF029228CACNA1G; 17q22Cav3.1abrain, nervous systemα13.1Cav3.2α1HAF051946; AF073931CACNA1H; 16p13.3Cav3.2abrain, heart, kidney, liverα13.2Cav3.3α1IAF086827CACNA1I; 22q12.3-13-2Cav3.3abrainα13.3The cloned voltage-gated Ca2+ channels and most widely studied alternate splice forms are presented together with the proposed nomenclature and previous nomenclatures.The nomenclature of the auxiliary subunits is not modified, since it already includes numbers for the gene family and lowercase letters for the splice variants. Thus, the subunit compositions of the voltage-dependent Ca2+ channels CaVn.mx may be described as α1n.mx/βm′x′/γm′′x′′/α2δm′′′x′′′ complexes, where the number n defines a main family, the numbers m, m′, m′′, and m′′′ refer to the individual genes/proteins within the families, and the letters x, x′, x′′, and x′′′ identify the splice variants. Standard prefixes can be placed in front of the channel name to identify the species of origin. In this notation, the skeletal muscle calcium channel would be written α11.1a/β1a/γ1a/α2δ1a. With this new nomenclature, the CaV designation may also be used to identify calcium channel auxiliary subunits such as CaVβ or CaVγ independent of their presence in a calcium channel complex.We hope that this new nomenclature for α1 subunits will be a stimulus to further research on voltage-gated Ca2+ channels by providing a common, easily accessible standard of reference for scientists working in this field. A full-length review article** is planned to present a more detailed proposal for nomenclature of the many alternate splice forms of the α1 subunits and the auxiliary subunits of Ca2+ channels that have been described in cDNA cloning experiments.*This nomenclature has been approved by the Nomenclature Committee of the International Union of Pharmacology, and a review article giving more details of the nomenclature for calcium channel subunits and splice variants is planned for Pharmacological Reviews.

Membrane organization of the dystrophin-glycoprotein complex

The stoichiometry, cellular location, glycosylation, and hydrophobic properties of the components in the dystrophin-glycoprotein complex were examined. The 156, 59, 50, 43, and 35 kd dystrophin-associated proteins each possess unique antigenic determinants, enrich quantitatively with dystrophin, and were localized to the skeletal muscle sarcolemma. The 156, 50, 43, and 35 kd dystrophin-associated proteins contained Asn-linked oligosaccharides. The 156 kd dystrophin-associated glycoprotein contained terminally sialylated Ser/Thr-linked oligosaccharides. Dystrophin, the 156 kd, and the 59 kd dystrophin-associated proteins were found to be peripheral membrane proteins, while the 50 kd, 43 kd, and 35 kd dystrophin-associated glycoproteins and the 25 kd dystrophin-associated protein were confirmed as integral membrane proteins. These results demonstrate that dystrophin and its 59 kd associated protein are cytoskeletal elements that are tightly linked to a 156 kd extracellular glycoprotein by way of a complex of transmembrane proteins.

Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage

Muscular dystrophies are a group of diseases that primarily affect skeletal muscle and are characterized by progressive muscle wasting and weakness. Although these diseases have been clinically recognized for a number of years, genetic defects in a number of muscular dystrophies have only recently been identified. One of the most important advances in understanding the molecular genetics of neuromuscular diseases has been the cloning of the gene encoding dystrophin, the protein absent in muscle of Duchenne muscular dystrophy (DMD) patients. In the last few years, the role of dystrophin in skeletal muscle has been studied, and several dystrophin-associated proteins (DAPs) have been identified. Components of the dystrophin-glycoprotein complex are now being characterized, and evidence is beginning to indicate that proteins of this complex may be responsible for other forms of muscular dystrophy. The present review focuses on the molecular basis of three muscular dystrophies (DMD, severe childhood autosomal recessive muscular dystrophy [SCARMD], and congenital muscular dystrophy [CMD]) that may be caused by disruptions in the dystrophin-glycoprotein complex, which normally links the subsarcolemmal cytoskeleton to the extracellular matrix in skeletal muscle.

Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies

Muscle–eye–brain disease (MEB) and Fukuyama congenital muscular dystrophy (FCMD) are congenital muscular dystrophies with associated, similar brain malformations. The FCMD gene, fukutin, shares some homology with fringe-like glycosyltransferases, and the MEB gene, POMGnT1, seems to be a new glycosyltransferase. Here we show, in both MEB and FCMD patients, that α-dystroglycan is expressed at the muscle membrane, but similar hypoglycosylation in the diseases directly abolishes binding activity of dystroglycan for the ligands laminin, neurexin and agrin. We show that this post-translational biochemical and functional disruption of α-dystroglycan is recapitulated in the muscle and central nervous system of mutant myodystrophy (myd) mice. We demonstrate that myd mice have abnormal neuronal migration in cerebral cortex, cerebellum and hippocampus, and show disruption of the basal lamina. In addition, myd mice reveal that dystroglycan targets proteins to functional sites in brain through its interactions with extracellular matrix proteins. These results suggest that at least three distinct mammalian genes function within a convergent post-translational processing pathway during the biosynthesis of dystroglycan, and that abnormal dystroglycan–ligand interactions underlie the pathogenic mechanism of muscular dystrophy with brain abnormalities.

Defective membrane repair in dysferlin-deficient muscular dystrophy

Muscular dystrophy includes a diverse group of inherited muscle diseases characterized by wasting and weakness of skeletal muscle. Mutations in dysferlin are linked to two clinically distinct muscle diseases, limb-girdle muscular dystrophy type 2B and Miyoshi myopathy, but the mechanism that leads to muscle degeneration is unknown. Dysferlin is a homologue of the Caenorhabditis elegans fer-1 gene, which mediates vesicle fusion to the plasma membrane in spermatids. Here we show that dysferlin-null mice maintain a functional dystrophin–glycoprotein complex but nevertheless develop a progressive muscular dystrophy. In normal muscle, membrane patches enriched in dysferlin can be detected in response to sarcolemma injuries. In contrast, there are sub-sarcolemmal accumulations of vesicles in dysferlin-null muscle. Membrane repair assays with a two-photon laser-scanning microscope demonstrated that wild-type muscle fibres efficiently reseal their sarcolemma in the presence of Ca2+. Interestingly, dysferlin-deficient muscle fibres are defective in Ca2+-dependent sarcolemma resealing. Membrane repair is therefore an active process in skeletal muscle fibres, and dysferlin has an essential role in this process. Our findings show that disruption of the muscle membrane repair machinery is responsible for dysferlin-deficient muscle degeneration, and highlight the importance of this basic cellular mechanism of membrane resealing in human disease.

Letter to the EditorNomenclature of Voltage-Gated Calcium Channels

As new Ca 2ϩ channel genes are cloned, it is apparent that these two alphabetical nomenclatures will overlap at ␣ 1L , which may not mediate an L-type Ca 2ϩ current and Voltage-gated Ca 2ϩ channels mediate calcium influx in therefore may create confusion. Moreover, the present response to membrane depolarization and regulate in-alphabetical nomenclature does not reveal the structural tracellular processes such as contraction, secretion, relationships among the ␣ 1 subunits, which can be neurotransmission, and gene expression. They are mem-grouped into three families: (1) ␣ 1S , ␣ 1C , ␣ 1D , and ␣ 1F ; (2) bers of a gene superfamily of transmembrane ion chan-The complete nel proteins that includes voltage-gated K ϩ and Na ϩ amino acid sequences of these ␣ 1 subunits are more channels. The Ca 2ϩ channels that have been character-than 70% identical within a family but less than 40% ized biochemically are complex proteins composed of identical among families. These family relationships are four or five distinct subunits, which are encoded by illustrated for the more conserved transmembrane and multiple genes. The ␣ 1 subunit of 190–250 kDa is the pore domains in Figure 1. Division of calcium channels largest subunit, and it incorporates the conduction pore, into these three families is phylogenetically ancient, as the voltage sensor and gating apparatus, and the known representatives of each are found in the C. elegans ge-sites of channel regulation by second messengers, nome. Ideally, a nomenclature for Ca 2ϩ channel ␣ 1 sub-drugs, and toxins. An intracellular ␤ subunit and a trans-units should provide a systematic organization based on membrane, disulfide-linked ␣ 2 ␦ subunit complex are their structural relationships and should be coordinated components of most types of Ca 2ϩ channels. A ␥ subunit with nomenclatures for the other families of voltage-has also been found in skeletal muscle Ca 2ϩ channels, gated ion channels of different ionic selectivities (ie., K ϩ and related subunits are expressed in heart and brain. and Na ϩ). Although these auxiliary subunits modulate the proper-For these reasons, we wish to propose a new nomen-ties of the channel complex, the pharmacological and clature of voltage-gated Ca 2ϩ channels (Table 1), which electrophysiological diversity of Ca 2ϩ channels arises is more systematic and mimics the well-defined K ϩ primarily from the existence of multiple forms of ␣ 1 sub-channel nomenclature (Chandy et al., 1991). This no-units. Mammalian ␣ 1 …

The mouse stargazer gene encodes a neuronal Ca2+-channel γ subunit

Stargazer mice have spike-wave seizures characteristic of absence epilepsy, with accompanying defects in the cerebellum and inner ear. We describe here a novel gene, Cacng2, whose expression is disrupted in two stargazer alleles. It encodes a 36-kD protein (stargazin) with structural similarity to the γ subunit of skeletal muscle voltage-gated calcium (Ca 2+) channels. Stargazin is brain-specific and, like other neuronal Ca2+-channel subunits, is enriched in synaptic plasma membranes. In vitro, stargazin increases steady-state inactivation of α 1 class A Ca2+ channels. The anticipated effect in stargazer mutants, inappropriate Ca2+ entry, may contribute to their more pronounced seizure phenotype compared with other mouse absence models with Ca2+-channel defects. The discovery that the stargazer gene encodes a γ subunit completes the identification of the major subunit types for neuronal Ca2+ channels, namely α1, α 2δ, β and γ, providing a new opportunity to understand how these channels function in the mammalian brain and how they may be targeted in the treatment of neuroexcitability disorders.

Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy.

Fukuyama congenital muscular dystrophy (FCMD), muscle–eye–brain disease (MEB), and Walker–Warburg syndrome are congenital muscular dystrophies (CMDs) with associated developmental brain defects. Mutations reported in genes of FCMD and MEB patients suggest that the genes may be involved in protein glycosylation. Dystroglycan is a highly glycosylated component of the muscle dystrophin–glycoprotein complex that is also expressed in brain, where its function is unknown. Here we show that brain-selective deletion of dystroglycan in mice is sufficient to cause CMD-like brain malformations, including disarray of cerebral cortical layering, fusion of cerebral hemispheres and cerebellar folia, and aberrant migration of granule cells. Dystroglycan-null brain loses its high-affinity binding to the extracellular matrix protein laminin, and shows discontinuities in the pial surface basal lamina (glia limitans) that probably underlie the neuronal migration errors. Furthermore, mutant mice have severely blunted hippocampal long-term potentiation with electrophysiologic characterization indicating that dystroglycan might have a postsynaptic role in learning and memory. Our data strongly support the hypothesis that defects in dystroglycan are central to the pathogenesis of structural and functional brain abnormalities seen in CMD.

Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy

Enteroviruses such as Coxsackievirus B3 can cause dilated cardiomyopathy, but the mechanism of this pathology is unknown. Mutations in cytoskeletal proteins such as dystrophin cause hereditary dilated cardiomyopathy, but it is unclear if similar mechanisms underlie acquired forms of heart failure. We demonstrate here that purified Coxsackievirus protease 2A cleaves dystrophin in vitro as predicted by computer analysis. Dystrophin is also cleaved during Coxsackievirus infection of cultured myocytes and in infected mouse hearts, leading to impaired dystrophin function. In vivo, dystrophin and the dystrophin-associated glycoproteins α-sarcoglycan and β-dystroglycan are morphologically disrupted in infected myocytes. We suggest a molecular mechanism through which enteroviral infection contributes to the pathogenesis of acquired forms of dilated cardiomyopathy.

Molecular basis of muscular dystrophies.

Muscular dystrophies represent a heterogeneous group of disorders, which have been largely classified by clinical phenotype. In the last 10 years, identification of novel skeletal muscle genes including extracellular matrix, sarcolemmal, cytoskeletal, cytosolic, and nuclear membrane proteins has changed the phenotype‐based classification and shed new light on the molecular pathogenesis of these disorders. A large number of genes involved in muscular dystrophy encode components of the dystrophin‐glycoprotein complex (DGC) which normally links the intracellular cytoskeleton to the extracellular matrix. Mutations in components of this complex are thought to lead to loss of sarcolemmal integrity and render muscle fibers more susceptible to damage. Recent evidence suggests the involvement of vascular smooth muscle DGC in skeletal and cardiac muscle pathology in some forms of sarcoglycan‐deficient limb‐girdle muscular dystrophy. Intriguingly, two other forms of limb‐girdle muscular dystrophy are possibly caused by perturbation of sarcolemma repair mechanisms. The complete clarification of these various pathways will lead to further insights into the pathogenesis of this heterogeneous group of muscle disorders.